{"result": "(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association (ATA) is a professional organization that provides guidelines and recommendations for thyroid health and treatment.)\n##\n(\"entity\"<|>MEN2<|>EVENT<|>MEN2 is a rare disease caused by activating mutations in the RET proto-oncogene, inherited in an autosomal dominant manner, associated with various tumors.)\n##\n(\"entity\"<|>RET PROTO-ONCOGENE<|>ORGANIZATION<|>The RET proto-oncogene is a gene that, when mutated, is associated with multiple endocrine neoplasia type 2 (MEN2) and related syndromes.)\n##\n(\"entity\"<|>CALCITONIN<|>ORGANIZATION<|>Calcitonin is a hormone produced by the thyroid gland, used as a marker in the diagnosis and management of thyroid conditions, particularly in MEN2.)\n##\n(\"entity\"<|>CMT<|>EVENT<|>CMT, or medullary thyroid carcinoma, is a type of cancer that occurs in the thyroid gland and is associated with MEN2.)\n##\n(\"entity\"<|>HYPERPARATHYROIDISM<|>EVENT<|>Hyperparathyroidism is a condition associated with MEN2, characterized by excessive secretion of parathyroid hormone.)\n##\n(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Feocromocitoma is a tumor of the adrenal gland that can occur in patients with MEN2, particularly in MEN2B.)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>MEN2<|>The American Thyroid Association provides updated recommendations regarding the management and screening of MEN2.<|>8)\n##\n(\"relationship\"<|>MEN2<|>RET PROTO-ONCOGENE<|>MEN2 is caused by mutations in the RET proto-oncogene, which is critical for understanding the disease's genetic basis.<|>9)\n##\n(\"relationship\"<|>MEN2<|>CALCITONIN<|>Calcitonin levels are used to stratify risk and guide treatment decisions in patients with MEN2.<|>7)\n##\n(\"relationship\"<|>MEN2<|>CMT<|>CMT is a common manifestation of MEN2, occurring in nearly all patients with the syndrome.<|>9)\n##\n(\"relationship\"<|>MEN2<|>HYPERPARATHYROIDISM<|>Hyperparathyroidism is one of the conditions associated with MEN2, affecting a subset of patients.<|>6)\n##\n(\"relationship\"<|>MEN2<|>FEOCROMOCITOMA<|>Feocromocitoma occurs in about 50% of patients with MEN2B, linking it directly to the syndrome.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.        otros, antes de la extensión del CMT fuera de la glándula, lo que garantizaría en ambas\n                                                                                                                                                  situaciones su curación a largo plazo.\n\n\n\n404                                                                                                                                                                                                                                                         405\n---\n                                                                                                                                                                    METABOLISMO FOSFOCÁLCICO,                                           TUMORES                           7\n                                                                                                                                                                                                  NEUROENDOCRINOS Y                                MEN\n\n\n\n     En 2015, la American Thyroid Association (ATA) Task Force actualizó sus recomendaciones                                                 37  Respecto a la neoplasia endocrina múltiple tipo 2 (MEN2), señale la respuesta\n     sobre la edad en la que se debería realizar una tiroidectomía total profiláctica. Estas reco-                                               cierta:\n     mendaciones están basadas en un modelo que utiliza la correlación genotipo-fenotipo para\n     estratificar las mutaciones RET en tres niveles de riesgo diferentes: moderado (MOD), alto                                                  A. Es muy frecuente la aparición de insulinoma.\n     riesgo (H) y categoría de más alto riesgo (HST) (tabla 4).                                                                                  B. En el MEN2B, el carcinoma medular de tiroides es más agresivo y precoz que\n                                                                                                                                                     en el MEN2A.\n     Tabla 4. Niveles de riesgo de las mutaciones del protooncogén RET y recomendaciones                                                         C. Los pacientes con MEN2A suelen tener fenotipo marfanoide.\n     de cribado y tratamiento (ATA, 2015)                                                                                                        D.  El diagnóstico genético no tiene utilidad clínica.\n          NIVEL DE                                         EDAD PARA TIROIDECTOMÍA                 EDAD DE INICIO PARA\n           RIESGO              MUTACIONES                      TOTAL PROFILÁCTICA                   EL CRIBADO DE FEOY HPP (ANUAL)               COMENTARIO\n       Muy alto (HST)              M918T                              <6 meses                        11 años (no HPP)                           MEN2 es una enfermedad rara debida a mutaciones activantes en el protooncogén RET que\n                                C634, A883F                                                                 11 años                              se hereda de forma autosómica dominante. El diagnóstico genético es importante porque\n           Alto (H)           V804M + E805K,                      5 años o antes si                  (no en mutaciones                           además de confirmar el diagnóstico e identificar a los portadores asintomáticos, es útil en\n                              V804M + Y806C,                     calcitonina elevada                asociadas a MEN2B)                           el seguimiento y tratamiento de estos pacientes porque existe correlación genotipo-feno-\n                              V804M + S904C                                                                                                      tipo, es decir, las diferentes mutaciones están asociadas con distintos riesgos de desarro-\n          Moderado                                       Controles anuales de calcitonina                                                        llar los tumores asociados a estos síndromes y también con la edad de presentación de\n            (MOD)          Resto de mutaciones           y ecografía Tiroidectomía total si                 16 años                              los tumores. Además, los dos síndromes de MEN2 (MEN2A y MEN2B) están asociados a\n                                                                 calcitonina elevada                                                             distintas mutaciones en el protooncogén RET.\n     FEO: feocromocitoma; HPP: hiperparatiroidismo primario.                                                                                     El síndrome MEN2A clásico se caracteriza por carcinoma medular de tiroides en el 100%,\n     Esta nueva clasificación tiene en cuenta la gran heterogeneidad en la presentación clínica                                                  feocromocitomas bilaterales en el 50% de los pacientes y HPP en el 20-30%. Esta prevalen-\n     en pacientes con la misma mutación, la mayor sensibilidad y especificidad de los ensayos                                                    cia varía en función del tipo de mutación.\n     de inmunoquimioluminiscencia para la determinación de calcitonina, y recientes estudios                                                     El síndrome MEN2B (también conocido como MEN3) es la forma más rara y agresiva de\n     que han demostrado que el nivel de calcitonina plasmática puede diferenciar entre hiper-                                                    MEN2; el CMT ocurre en la 1.ª-2.ª década de la vida, incluso se ha descrito a los pocos días\n     plasia de las células C, CMT confinado en la glándula tiroidea y CMT con expansión gan-                                                     de vida; tiende a ser más agresivo y con peor pronóstico letal que MEN2A.\n     glionar. Por ello, para orientar el momento y el tipo de intervención quirúrgica recomiendan\n     valorar el genotipo, la ecografía tiroidea y el valor de la calcitonina basal (la mayoría de                                                El síndrome MEN2B se              asocia a     feocromocitomas en           el  50% de los pacientes,          pero   se\n     los autores consideran que dada su sensibilidad no es necesario realizar test de est\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}